Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Barb Helfrich"'
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 59:S27-S38
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small-cell lung cancers (NSCLCs). This presents an opportune target for new treatment strategies designed to selectively interfere with the cancer cell growth cycle.
Publikováno v:
Lung Cancer. 41:15-22
The development of rationally designed agents targeting specific biological pathways in tumor development has been heralded as a major paradigm shift in the approach to the treatment of cancer. The application of these agents has lead to promising pr
Autor:
David Raben, Barb Helfrich
Publikováno v:
Clinical lung cancer. 6(1)
Angiogenesis is a precondition to invasion and metastasis for all solid tumors. Vascular endothelial growth factor (VEGF) and its family of receptors (VEGFR) play a critical role in cancer progression by promoting new blood vessel formation. Overexpr
Autor:
Fortunato Ciardiello, David Raben, Elaine Weng, Cataldo Bianco, Paul M. Harari, Barb Helfrich
Publikováno v:
Scopus-Elsevier
The introduction of biologically active agents that interfere with the epidermal growth factor receptor (EGFR) provides a promising opportunity to improve cancer treatment outcomes. Several EGFR-selective agents, such as humanized monoclonal antibodi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63cdc7acbf055c094b196ced81521a23
http://hdl.handle.net/11591/223545
http://hdl.handle.net/11591/223545